Coherus Fends Off Amgen’s Pegfilgrastim Purification Patent Case

 
• By Aidan Fry

Coherus’ manufacturing process for its Udenyca pegfilgrastim biosimilar does not infringe a US purification patent held by Amgen, the US Court of Appeals has confirmed.

Chromatography
Coherus' chromatography steps for purifying pegfilgrastim do not infringe Amgen's US patent, the US Court of Appeals has confirmed • Source: Shutterstock

More from Biosimilars

More from Products